Ryan Parke, CASUDC | |
474 W 200 N Ste 200, St George, UT 84770-4505 | |
(435) 634-5600 | |
Not Available |
Full Name | Ryan Parke |
---|---|
Gender | Male |
Speciality | Social Worker |
Location | 474 W 200 N Ste 200, St George, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518436914 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | 10564656-6018 (Utah) | Secondary |
104100000X | Social Worker | 10564656-3502 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ryan Parke, CASUDC 474 W 200 N Ste 200, St George, UT 84770-4505 Ph: (435) 634-5600 | Ryan Parke, CASUDC 474 W 200 N Ste 200, St George, UT 84770-4505 Ph: (435) 634-5600 |
News Archive
A study led by University of North Carolina at Chapel Hill researchers using brain imaging of infants to examine changes in their brains and behavior that may mark the onset of autistic symptoms is being substantially expanded after receiving an additional $3.25 million in funding.
Cardiovascular Systems, Inc., announced today that it has established a $25 million credit facility with Silicon Valley Bank and up to $4 million in convertible debt with Partners for Growth. Proceeds will be used to consolidate existing outstanding debt, provide working capital for growth and for general corporate purposes.
Older veterans who experienced traumatic brain injury showed a more than two-fold increase in the risk of developing dementia, according to new research presented today at the Alzheimer's Association® International Conference 2011 (AAIC 2011) in Paris.
HealthBridge Management, which operates five Health Care Centers in Connecticut currently subject to a strike by the New England Health Care Employees Union, District 1199 SEIU (the Union), today provided an update on events as the strike, which began July 3, continued into its third week.
POZEN Inc. announced today the start of enrollment for the phase 3 studies for PA32540. PA32540 is a fixed-dose combination of 325 mg of enteric coated aspirin and 40 mg of immediate release omeprazole, under investigation for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers.
› Verified 7 days ago